Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial-Reference-Cited by-同舟云学术

Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial

Published:2018-03-28 Issue:1 Volume:108 Page:39-46
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Isoda Atsushi^ORCID, ,Murayama Kayoko,Ito Shigeki,Kohara Yoichi,Iino Masaki,Miyazawa Yuri,Matsumoto Morio,Handa Hiroshi,Imai Yosuke,Ishiguro Takuro,Izumita Wataru,Kitano Kiyoshi,Hirabayashi Yukio,Nakazawa Hideyuki,Ishida Fumihiro,Mitsumori Toru,Kirito Keita,Chou Takaaki,Murakami Hirokazu

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-018-2448-9/fulltext.html

Reference26 articles.

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.

2. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680–5.

3. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet. 1992;339(8787):200–5.

4. Alexanian R, Gehan E, Haut A, Saiki J, Weick J. Unmaintained remissions in multiple myeloma. Blood. 1978;51(6):1005–11.

5. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB, et al. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979;301(14):743–8.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrochemical Protein-based Bioanalytical Devices for Drug Analysis;Current Topics in Medicinal Chemistry;2023-06

2. Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients;Critical Reviews in Oncology/Hematology;2022-08

3. Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study;Cancer Medicine;2021-10-16

4. Proteasome Inhibitors for the Treatment of Multiple Myeloma;Cancers;2020-01-22

5. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial;The Lancet;2019-01